|
| Press Releases |
|
 |
|
| Friday, May 27, 2022 |
|
|
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO22), which is taking place virtually and in-person in Chicago from June 3 to 7. more info >> |
|
|
Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS |
| Eisai Co., Ltd. announced today that it has received orphan drug designation for ultrahigh-dose mecobalamin, with a prospective indication for delaying the progression of disease and functional impairment of amyotrophic lateral sclerosis (ALS), by the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Tuesday, May 10, 2022 |
|
|
Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway. more info >> |
|
|
Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan |
| Eisai Co., Ltd. today announced that it has initiated preparation on a New Drug Application for ultrahigh-dose mecobalamin. more info >> |
|
| Friday, April 1, 2022 |
|
|
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business |
| Eisai Co., Ltd. announced today that Eisai has acquired a majority of the shares issued by Arteryex Inc., a company that plans and develops software related to digital solutions such as provision of medical information platforms, through purchase of shares and subscription of a third-party allocation of common shares, and made it a subsidiary, as of March 31, 2022. more info >> |
|
| Monday, March 28, 2022 |
|
|
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor |
| Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced that Gilead acquired an approval of additional indication of Jyseleca, Janus Kinase (JAK) inhibitor, for the treatment of patients with active moderate-to-severe ulcerative colitis in Japan. more info >> |
|
| Tuesday, March 22, 2022 |
|
|
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) March 15-20 in Barcelona, Spain and virtually. more info >> |
|
| Tuesday, March 15, 2022 |
|
|
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen |
| Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer's disease collaboration agreement with Biogen Inc. separately announced today. more info >> |
|
|
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments |
| Biogen Inc. and Eisai Co., Ltd. announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM (aducanumab-avwa). more info >> |
|
| Friday, March 11, 2022 |
|
|
Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting |
| Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Melbourne's Deputy Lord Mayor shares city's path forward at PropertyGuru Asia Property Awards (Australia) launch
Apr 29, 2025 23:58 HKT/SGT
|
|
|
Global Sports Brand U.S. Polo Assn. Delivers Record $2.5 Billion in Retail Sales for 2024, Targets $3 Billion and 1,500 U.S. Polo Assn. Stores
Apr 29, 2025 22:48 HKT/SGT
|
|
|
The Apipatana Foundation Donates S$50,000 to Support Lower-Income Students in Singapore
Apr 29, 2025 22:47 HKT/SGT
|
|
|
HydroFleet Propels Hydrogen Revolution Forward With HTWO Logistics Collaboration in Savannah, GA
Apr 29, 2025 22:47 HKT/SGT
|
|
|
DataBurning and Vumonic Announce Strategic Partnership for India E-Receipt Data
Apr 29, 2025 22:46 HKT/SGT
|
|
|
Katalon Officially Launches TrueTest(TM) - The First AI-Native Testing System That Thinks Like a Tester and Learns from Users
Apr 29, 2025 22:00 HKT/SGT
|
|
|
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of Large Car Ferry KEYAKI in Shimonoseki
Apr 29, 2025 17:24 JST
|
|
|
Open Dialogue 'Future of the World. New Platform for Global Growth' Launches at Russia National Centre 
Apr 29, 2025 15:00 HKT/SGT
|
|
|
HKTDC's April lifestyle fairs open today
Apr 29, 2025 12:42 HKT/SGT
|
|
|
Azurite Medical and Wellness Launches Revolutionary Luxury Surgical Retreat Concept in Global Medical Tourism Market
Apr 29, 2025 02:09 HKT/SGT
|
|
|
Hong Kong International Licensing Show and Asian Licensing Conference Open Today
Apr 28, 2025 22:46 HKT/SGT
|
|
|
Hung Fook Tong Partners with Nutribite to Launch AI-Powered Personalised Healthy Meal Service
Apr 28, 2025 15:51 HKT/SGT
|
|
|
Q2 Metals Extends Mineralized Zone Strike Length to 1.5 Kilometres and Concludes the 2025 Winter Program at the Cisco Lithium Project in Quebec, Canada
Apr 28, 2025 15:05 HKT/SGT
|
|
|
NEC DGDF Headquarters relocates to Zurich to accelerate growth and enhance management globally
Apr 28, 2025 16:03 JST
|
|
|
Wintermar Offshore (WINS:JK) Reports 1Q2025 Results
Apr 28, 2025 11:25 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
